We are seeking an experienced scientist to drive development and production of MHCs (Major Histocompatibility Complex). You must be self-motivated, detail-oriented and highly experienced scientist with a proven background in protein expression, refolding and purification of proteins.
We are seeking an experienced scientist to drive our ImmPACT scaffold development. You must be self-motivated, detail-oriented and a highly experienced scientist with a proven background in development of downstream TFF purification processes, and with extensive knowledge in protein formulation, stability and characterization.
We are seeking an experienced scientist to drive our cell culture process development. You need to be independent, detail-oriented and still have the passion for being in the lab, as we are in startup mode.
BioInnovation Institute has selected PokeAcell as one of four companies to join their Creatio House program from April 1, 2020. During the program PokeAcell will access financing of 10 M DKK and the excellent facilities and business development capacities at BII. PokeAcell is excited to join the other great start ups at BII and bringing our ImmPACT T cell product one step closer to helping solid tumor patients without proven treatment options today.
Today, Sine R. Hadrup, will receive the prestigious Elite Research Prize from the Ministry of Higher Education and Science. The Elite Research Prize is awarded to outstanding researchers under 45 years of international excellence. Sine receives this award for her outstanding research in immunotherapy of cancer and more specifically her research in educating the immunesystem to fight cancer through T cell recognition and activation.
PokeAcell has secured exclusive licensing rights to a proprietary technology, for personalized T cell therapy. The new technology can activate and grow cancer-specific T cells present in patient’s own blood and the cells can then be given back to the patient as fully personalized treatment. The T cell therapy hold the potential of curative treatment in Metastatic Melanoma and Merkel Cell carcinoma – two of the most severe skin cancers today and with potential in several other indications.
Follow us on LinkedIn